Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Sector news Pharmaceuticals - NEC
02/16S&P 500 caps off strongest week in five years
RE
02/16ASTRAZENECA : U.S. FDA approves AstraZeneca's immunotherapy for lung cancer
RE
02/16NOVARTIS : readies to auction U.S. generic pills business - sources
RE
02/16Backstory - Warren Buffett's Valentine's Day surprise for investors
RE
02/16BACKSTORY : Warren Buffett's Valentine's Day surprise for investors
RE
02/16WARREN BUFFETT : Warren Buffett's Valentine's Day surprise for investors
RE
02/16Pot Pharm - Booming Canada weed sector plots next-wave medicines
RE
02/16POT PHARM : Booming Canada weed sector plots next-wave medicines
RE
02/15ROCHE : to buy Flatiron Health for $1.9 billion to expand cancer care portfolio
RE
02/15ROCHE : to buy Flatiron Health for $1.9 billion to expand cancer care portfolio
RE
02/15ROCHE : to Acquire Healthcare-Software Company Flatiron for $1.9 Billion
DJ
02/15AbbVie to buy back $10 billion of shares, raises dividend
RE
02/15AbbVie to buy back $10 billion of shares, raises dividend
RE
02/15ABBVIE : Increases Dividend and Announces New Stock Repurchase Program
DJ
02/15Cyclicals, South Africa-exposed stocks help steady FTSE 100
RE
02/15European shares build on recovery, Airbus shines
RE
02/15SANOFI : Correction to Sanofi Dengue Vaccine Article on Feb. 2
DJ
02/15MERCK : and Pfizer's Avelumab Fails to Meet Endpoint in Lung Cancer Trial -- Upd..
DJ
02/15MERCK : and Pfizer's Avelumab Fails to Meet Endpoint in Lung Cancer Trial
DJ
02/15Growth formula eludes under-fire Nestle, L'Oreal stake unchanged
RE
02/15Indivior bets on $1 billion anti-addiction shot as legal bill weighs
RE
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15SHIRE PLC SHIRE PLC : Director/Pdmr Shareholding
DJ
02/15BAYER : Syngenta aims to sell bonds within weeks, M&A important - CFO
RE
02/15COLOPLAST A/S : ConvaTec beats low full-year expectations, shares rise
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/15ASTRAZENECA : Says Selumetinib Granted FDA Orphan Drug Status
DJ
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14SHIRE : 4Q Product Sales and Generic Competition in Focus -- Earnings Review
DJ
02/14BAYER : Gets FDA Warning Over Manufacturing Practices at German Site
DJ
02/14SHIRE : 4Q Profit Rises on U.S. Tax Reform
DJ
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/14SHIRE PLC SHIRE PLC : Final Results -9-
DJ
02/14SHIRE PLC SHIRE PLC : Final Results -8-
DJ
02/14SHIRE PLC SHIRE PLC : Final Results -7-
DJ
02/14SHIRE PLC SHIRE PLC : Final Results -6-
DJ
02/14SHIRE PLC SHIRE PLC : Final Results -5-
DJ
02/14SHIRE PLC SHIRE PLC : Final Results -4-
DJ
02/14SHIRE PLC SHIRE PLC : Final Results -3-
DJ
02/14SHIRE PLC SHIRE PLC : Final Results -2-
DJ
02/14SHIRE PLC SHIRE PLC : Final Results
DJ
02/14BAYER : gets FDA rebuke for drug production in Germany
RE
02/13Commodities help FTSE 100 outperform European stocks
RE
02/13BAYER : Taking Russia Antitrust Authorities to Court Over Monsanto
DJ
02/13Novartis gains U.S. approval for delayed MS drug
RE
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
02/13OPIOID MAKERS PAID MILLIONS TO ADVOC : U.S. Senate report
RE
02/12SANOFI : and SK Chemicals Sign Licensing Agreement for Flu Vaccine Technology
DJ
02/12NOVARTIS : Greek PM wants politicians investigated in alleged Novartis bribery c..
RE
02/12AXOVANT SCIENCES : CEO David Hung resigns, shares tumble
RE
Financials ($)
Sales 2018 41 616 M
EBIT 2018 13 718 M
Net income 2018 8 465 M
Debt 2018 13 842 M
Yield 2018 3,43%
P/E ratio 2018 17,24
P/E ratio 2019 13,87
EV / Sales 2018 4,00x
EV / Sales 2019 3,84x
Capitalization 153 B
Sector Pharmaceuticals - NEC
1st jan.Capitalization (M$)
MERCK AND COMPANY-0.50%149 572
JOHNSON & JOHNSON-7.19%352 552
NOVARTIS-3.37%224 301
PFIZER-2.84%212 857
ROCHE HOLDING LTD.-9.37%210 327
AMGEN3.23%133 277
BRISTOL-MYERS SQUIBB COMPANY6.64%112 900
ABBOTT LABORATORIES2.12%101 442
BAYER-6.36%100 998
NOVO NORDISK A/S-8.76%100 858
SANOFI-11.62%100 587
GLAXOSMITHKLINE-1.67%91 131
ELI LILLY AND COMPANY-8.80%85 907
ASTRAZENECA-7.96%83 544
CELGENE CORPORATION-9.55%70 998
ALLERGAN PLC1.86%55 418
TAKEDA PHARMACEUTICAL CO LTD-8.48%44 448
SHIRE-18.46%40 492
JIANGSU HENGRUI MEDICINE CO LTD4.28%32 119
ASTELLAS PHARMA INC2.52%28 725
CHUGAI PHARMACEUTICAL CO LTD-6.07%28 258